In a podcast that goes live today, The American Journal of Managed Care® paired Mandi Bishop, MA, the CEO of Aloha Health, with Andy Slavitt, MBA, who is finishing his tenure as acting administrator of the Centers for Medicare & Medicaid Services. Bishop asked Slavitt about the lessons of payment reform, the impact of MACRA, and what the new administration should expect.
FOR IMMEDIATE RELEASEJanuary 5, 2017
PLAINSBORO, N.J.—At its heart, the Centers for Medicare & Medicaid Services (CMS) is a service organization that doesn’t just create health policy, but also asks, “how do we bring the policy to the kitchen table of the American family?” CMS Acting Administrator Andy Slavitt, MBA, says in a new podcast that goes live today. (For the podcast, click here.)
Slavitt joined Mandi Bishop, MA, for an installment of Managed Care Cast, produced by The American Journal of Managed Care.® Bishop, CEO of Aloha Health, took Slavitt through a tour of his healthcare experiences, from founding Health Allies to assist uninsured and underinsured patients, to the implementation of the 2015 Medicare Access and CHIP Reauthorization Act (MACRA), which Slavitt described as “the beginning of the next stage of the Medicare program.”
CMS is always a huge job, as the agency serves 140 million people across Medicare, Medicaid, and the Children’s Health Insurance Program (CHIP). But Slavitt’s tenure has been especially eventful: he oversaw the third and fourth rounds of open enrollment under the Affordable Care Act, and he set loose a burst of new payment models to move healthcare from a fee-for-service to a value-based system. On his watch, President Barack Obama’s administration set the ambitious goal of making 50% of all Medicare payments value-based by 2018.
Bishop observed that making healthcare policy translatable, with tools that let Americans find the best hospitals or help doctors use quality care measures, has been a hallmark of Slavitt’s tenure. “It’s really a service job,” Slavitt said of CMS. “Day-to-day service to 140 million Americans is really what unites the work we do.”
Slavitt shared his perspectives on where value-based care is headed, and offered insights for the incoming administration of President-elect Donald J. Trump:
· MACRA, he said, will impact the practice of medicine beyond Medicare. But it will fail if providers only worry about “score-keeping” and don’t seize the opportunity to build upon and reward successful patient-provider relationships.
· MACRA must speak to small practices that are vital to bringing good care to vast parts of the country. If it becomes too complicated, Slavitt said, “you’ll have small practices that decide to give up,” which would be disastrous for healthcare delivery.
· Value-based models are designed to reward those health systems that have created a culture of quality but need tools to make this commitment work financially, he said. “My experience has been there is absolutely nothing that a commercial payer or CMS could do which changes the capabilities of a healthcare community to provide better care unless it’s already supporting cultural, clinical leadership that knows what it wants to do, and is basically waiting for the support and resources,” Slavitt said.
· Payment reform has instilled the idea that healthcare works best when there’s an ongoing relationship between the patient and the provider. When teams work with patients over time, he said, “they know when the patient just isn’t filling the medication because they aren’t going to have the co-payment this month,” or when they need behavioral health services.
Bishop asked how the Trump administration will address ongoing challenges, and Slavitt declined to respond. He said the new team deserved a chance to execute its vision. That said, Slavitt said, “When you’re in one of these roles … you quickly realize you work for the American public,” which means balancing concerns from across the spectrum—and taking steps to seek opinions from groups that can’t afford a lobbyist.
The Trump team, he said, “will work for us just like I work for you now, and that means they will need to hear from us about what the challenges and priorities are.”
About the Journals and AJMC.com
The American Journal of Managed Care® is the leading peer-reviewed journal dedicated to issues in managed care. AJMC.com distributes healthcare news to leading stakeholders across a variety of platforms. Other titles in the franchise include The American Journal of Accountable Care®, which publishes research and commentary on innovative healthcare delivery models facilitated by the 2010 Affordable Care Act, and The American Journal of Pharmacy Benefits. ® AJMC®’s Evidence-Based series brings together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC® publications, please call (609) 716-7777, x 131.
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More